132 related articles for article (PubMed ID: 11389126)
41. Comparative in vitro activity of moxifloxacin against Gram-positive clinical isolates.
Hoogkamp-Korstanje JA; Roelofs-Willemse J
J Antimicrob Chemother; 2000 Jan; 45(1):31-9. PubMed ID: 10629010
[TBL] [Abstract][Full Text] [Related]
42. Resistance of Streptococcus pneumoniae to fluoroquinolones--United States, 1995-1999.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Sep; 50(37):800-4. PubMed ID: 11785571
[TBL] [Abstract][Full Text] [Related]
43. Comparison of in vitro susceptibilities of Gram-positive cocci isolated from ocular infections against the second and fourth generation quinolones at a tertiary eye care centre in South India.
Reddy AK; Garg P; Alam MR; Gopinathan U; Sharma S; Krishnaiah S
Eye (Lond); 2010 Jan; 24(1):170-4. PubMed ID: 19229279
[TBL] [Abstract][Full Text] [Related]
44. Sparfloxacin, a new generation fluoroquinolone against S. pneumoniae respiratory infections.
Niki Y; Tamada S; Nakabayashi M; Soejima R
Drugs; 1995; 49 Suppl 2():420-2. PubMed ID: 8549385
[No Abstract] [Full Text] [Related]
45. [Moxifloxacin: results of clinical use].
Iakovlev VP; Polushkina NR
Antibiot Khimioter; 2002; 47(10):32-6. PubMed ID: 12674792
[No Abstract] [Full Text] [Related]
46. Moxifloxacin: new indication. Inadequate restriction of indications in ENT and respiratory infections.
Prescrire Int; 2009 Oct; 18(103):206. PubMed ID: 19882787
[TBL] [Abstract][Full Text] [Related]
47. Fluoroquinolone resistance in Streptococcus pneumoniae.
Kuehnert MJ; Nolte FS; Perlino CA
Ann Intern Med; 1999 Aug; 131(4):312-3. PubMed ID: 10454959
[No Abstract] [Full Text] [Related]
48. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
49. Gemifloxacin: survival of the fittest.
Mandell L
J Antimicrob Chemother; 2000 Jul; 46 Suppl T1():33-7. PubMed ID: 10997597
[TBL] [Abstract][Full Text] [Related]
50. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Esposito S; Noviello S; Ianniello F
J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
[TBL] [Abstract][Full Text] [Related]
51. [Moxifloxacin--a novel antimicrobial preparation for treatment of respiratory infections].
Iakovlev SV; Polushkina NR; Iakovlev VP
Ter Arkh; 2001; 73(11):15-22. PubMed ID: 11806197
[No Abstract] [Full Text] [Related]
52. Comparative efficacy of besifloxacin and other fluoroquinolones in a prophylaxis model of penicillin-resistant Streptococcus pneumoniae rabbit endophthalmitis.
Norcross EW; Sanders ME; Moore Q; Sanfilippo CM; Hesje CK; Shafiee A; Marquart ME
J Ocul Pharmacol Ther; 2010 Jun; 26(3):237-43. PubMed ID: 20565309
[TBL] [Abstract][Full Text] [Related]
53. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
54. Topical ophthalmic fourth-generation fluoroquinolones: Appropriate use and cost considerations.
Fiscella RG; Lewis CC; Jensen MK
Am J Health Syst Pharm; 2007 Oct; 64(19):2069-73. PubMed ID: 17893419
[TBL] [Abstract][Full Text] [Related]
55. Antipneumococcal activity of DW-224a, a new quinolone, compared to those of eight other agents.
Kosowska-Shick K; Credito K; Pankuch GA; Lin G; Bozdogan B; McGhee P; Dewasse B; Choi DR; Ryu JM; Appelbaum PC
Antimicrob Agents Chemother; 2006 Jun; 50(6):2064-71. PubMed ID: 16723567
[TBL] [Abstract][Full Text] [Related]
56. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809
[TBL] [Abstract][Full Text] [Related]
57. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
58. Clinical perspectives on new antimicrobials: focus on fluoroquinolones.
Talan DA
Clin Infect Dis; 2001 Mar; 32 Suppl 1():S64-71. PubMed ID: 11249831
[TBL] [Abstract][Full Text] [Related]
59. Penicillin enhances the toll-like receptor 2-mediated proinflammatory activity of Streptococcus pneumoniae.
Moore LJ; Pridmore AC; Dower SK; Read RC
J Infect Dis; 2003 Oct; 188(7):1040-8. PubMed ID: 14513425
[TBL] [Abstract][Full Text] [Related]
60. In vitro activity of novel fluoroquinolones against Streptococcus pneumoniae isolated from children with acute otitis media.
Yagupsky P; Katz O; Peled N; Dagan R
Chemotherapy; 2001; 47(5):354-8. PubMed ID: 11561138
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
